Published in Nat Rev Urol on May 08, 2012
Don't run before you can walk. Nat Rev Urol (2012) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 1.73
Side effects of corticosteroid therapy. J Clin Gastroenterol (2001) 1.60
Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect (2005) 0.88
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst (2007) 2.24
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst (2003) 2.16
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov (2011) 1.52
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol (2003) 1.51
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev (2010) 1.49
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther (2003) 1.39
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
Harnessing the power of the immune system to target cancer. Annu Rev Med (2012) 1.33
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med (2014) 1.18
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Targeting Src signaling in metastatic bone disease. Int J Cancer (2009) 1.07
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int (2011) 0.99
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
TAD: a web interface and database for tissue microarrays. Appl Bioinformatics (2002) 0.95
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun (2008) 0.93
Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy (2011) 0.90
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin (2007) 0.89
Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol (2005) 0.89
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.89
Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology (2011) 0.89
Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem (2002) 0.88
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett (2002) 0.87
Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol (2010) 0.86
Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther (2008) 0.85
Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines (2010) 0.84
How to get the most from microarray data: advice from reverse genomics. BMC Genomics (2014) 0.84
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics (2008) 0.84
Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc (2004) 0.83
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res (2013) 0.82
Genes with a large intronic burden show greater evolutionary conservation on the protein level. BMC Evol Biol (2014) 0.81
Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol (2005) 0.80
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol (2011) 0.78
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol (2013) 0.77
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell (2015) 0.76
5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 0.76
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2003) 0.75
Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature (2017) 0.75